

In the Claims:

Please cancel claim 7, 14, and 20.

Please amend claims 1 and 8 as set out below:

1. [AMENDED TWICE] A method for treating allergy symptoms not associated with respiratory congestion selected from the group consisting of headache, irritated eyes and lethargy in a patient, comprising the step of:

administering through a sublingual route in a manner so as not to effect gene transfer an effective amount of DNA in a pharmaceutically-acceptable vehicle to a patient having allergy symptoms such that the allergy symptoms not associated with respiratory congestion selected from the group consisting of headache, irritated eyes and lethargy are reduced.

8. [AMENDED TWICE] A method for treating the asthma symptom of constriction of airways which is not associated with respiratory congestion in a patient, comprising the steps of:

administering in a manner so as not to effect gene transfer a therapeutically effective amount of DNA in a pharmaceutically-acceptable vehicle to a patient having the asthma symptom of constriction of airways which is not associated with respiratory congestion is reduced.

REMARKS

I. Preliminary Comments

Applicants have amended the specification to clarify the term “injected” and to update the priority claim. The Patent Office objected to the phrase “injected tympanic membrane” on page 14, line 15 for being unclear and Applicants have amended “injected” to “infected.” This amendment corrects what was obviously a typographical error.